What Has Been The Evolution of the Gout Therapeutics Market in Recent Years?
The gout therapeutics market has seen considerable growth due to a variety of factors.
•In recent times, the gout therapeutics market has experienced a significant expansion in its size. It is forecasted to increase from $2.88 billion in 2024 to an estimated $3.23 billion in 2025, projecting a compound annual growth rate (CAGR) of 12.2%.
Factors contributing to this growth during the historical period include an upsurge in gout prevalence, alterations in lifestyle and dietary habits, high incidences of high blood pressure and diabetes, the emergence of xanthine oxidase inhibitors, as well as initiatives aimed at patient education.
What Is the Forecasted Market Size and Growth Rate for The Gout Therapeutics Market?
The gout therapeutics market is expected to maintain its strong growth trajectory in upcoming years.
• Anticipations are high for a quick expansion of the gout therapeutics market in the forthcoming years, with projections estimating it to surge to $5.03 billion by 2029 at a compound annual growth rate (CAGR) of 11.7%.
The increase during the prediction period can be accredited to several factors such as growth in healthcare spending, innovation in drug delivery systems, development of groundbreaking therapies, government-led efforts towards chronic disease management, as well as numerous patient advocacy and support groups. The prediction period is also expected to see significant trends such as inventive drug development, approval of groundbreaking drugs, personalized treatment methods, utilization of telehealth services for managing gout, as well as extensive research in the area of urate-lowering therapies.
What Are The Core Factors Supporting Growth In The Gout Therapeutics Market?
The escalating instances of gout are anticipated to stimulate the expansion of the gout therapeutics market. Gout, an inflammatory arthritis disorder, triggers pain and inflammation in the joints. The therapy for gout works by alleviating pain, swelling, and joint sensitivity. Consequently, the escalating prevalence of gout is projected to amplify sales within the gout therapeutic market. For illustration, the Australian Institute of Health and Welfare, a U.S. government entity, revealed in June 2024 that gout caused 573 deaths in Australia in 2022, corresponding to 2.2 fatalities per every 100,000 individuals. Thus, the growing prevalence of gout serves as a catalyst propelling the expansion of the gout therapeutics market.
What Are The Major Segments Within The Global Gout Therapeutics Market?
The gout therapeutics market covered in this report is segmented –
1) By Type: Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroid, Diuretics
2) By Treatment: Xanthine Oxidase Inhibitor, Uricosuria Medication
3) By Disease Condition: Acute, Chronic
4) By End-Users: Hospitals, Specialty Clinics, Other End Users
Subsegments:
1) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Traditional NSAIDs, Selective COX-2 Inhibitors
2) By Corticosteroid: Oral Corticosteroids, Injectable Corticosteroids
3) By Diuretics: Thiazide Diuretics, Loop Diuretics
Pre-Book The Gout Therapeutics Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Trends Are Expected To Transform The Gout Therapeutics Market?
The dominant trend gaining traction in the gout therapeutics market is product innovation. To maintain their market position, many major firms in this market are creating unique treatment methods. For example, in August 2022, Synlogic Inc., a pharmaceutical company based in the US, introduced a new drug contender for gout therapy called SYNB2081. This synthetic biotic is engineered to reduce uric acid levels and is the second clinical drug developed through a joint research partnership between Synlogic and Ginkgo, a biotech company also from the US.
Who Are the Key Players in the Gout Therapeutics Market?
Major companies operating in the gout therapeutics market include:
• Sanofi-Aventis
• AstraZeneca plc
• LG Chem Ltd.
• GlaxoSmithKline Plc
• Takeda Pharmaceuticals Co. Ltd.
• Boehringer Ingelheim International GmbH
• Regeneron Pharmaceuticals Inc.
• Astellas Pharma Inc.
• Sandoz
• Eisai Co. Ltd.
• Horizon Pharma Plc
• Jiangsu HengRui Medicine Co. Ltd.
• Hikma Pharmaceuticals plc
• Swedish Orphan Biovitrum AB
• JW Pharmaceutical Corp
• Lannett Company Inc
• BioCryst Pharmaceuticals Inc.
• Selecta Biosciences Inc.
• Rigel Pharmaceuticals Inc.
• CymaBay Therapeutics Inc.
• GeneScience Pharmaceuticals Co. Ltd.
• Shanton Pharma
What Is The Most Dominant Region In The Gout Therapeutics Market?
North America was the largest region in the gout therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gout therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
